Setmelanotide
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
Rhythm · Phase 3 · Completed · Enrollment 52
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Setmelanotide (Double-Blind) | Bardet Biedl Syndrome (BBS); Alström Syndrome... | n/r | 52 | n/r | n/r |
| Placebo (Double-Blind) | Bardet Biedl Syndrome (BBS); Alström Syndrome... | n/r | 52 | n/r | n/r |
| Setmelanotide (Open-label) | Bardet Biedl Syndrome (BBS); Alström Syndrome... | n/r | 52 | n/r | n/r |
| Pivotal Cohort | Bardet Biedl Syndrome (BBS); Alström Syndrome... | n/r | 52 | n/r | -5.21% at week 52 |